📅 2026 Update: Telehealth and Controlled Substances

Since the original article was published, there have been significant changes regarding telehealth and controlled substances in the U.S. The regulations now allow for easier access to prescriptions through telemedicine. These updates aim to improve patient care and treatment options, especially for those struggling with substance use disorders.

The earlier article continues further down the page, providing historical context and details about Pergolide-Permax.

🩺 Telemedicine Flexibilities Extended

The U.S. Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) have extended the telemedicine flexibilities for prescribing controlled substances. This extension is in effect through December 31, 2026.

Practitioners can now prescribe Schedule II-V medications via telehealth without needing an in-person visit.

💊 Buprenorphine Accessibility

A significant change occurred on January 17, 2025, when the DEA and HHS made permanent the telemedicine flexibilities for prescribing buprenorphine. This medication is crucial for treating opioid use disorder, allowing more patients to access care conveniently.

🏥 Strengthening Mental Health Parity

On September 9, 2024, new rules were released to reinforce the Mental Health Parity and Addiction Equity Act (MHPAEA). These rules ensure that mental health and substance use disorder benefits are treated the same as medical and surgical benefits. This change became effective on November 22, 2024, improving coverage for many individuals.

🗓️ No Deadlines for Buprenorphine Treatment

Patients can seek buprenorphine treatment through telemedicine at any time. There are no specific deadlines for initiating this treatment, allowing flexibility for those in need.

📌 Key Points Summary

  • Telemedicine Flexibilities: Extended through December 31, 2026.
  • Buprenorphine: Telemedicine prescribing made permanent.
  • Mental Health Coverage: New rules strengthen parity for mental health benefits.
  • No Deadlines: Buprenorphine treatment can be initiated anytime.

💡 Tips for Navigating Telehealth Prescriptions

It's essential to review the details of your situation with an attorney.

📹 Video Consultations Required

To obtain prescriptions for controlled substances via telehealth, patients must have a video consultation with a DEA-registered practitioner. This step is crucial for assessing medical history and prescribing needs.

🌐 Check Provider Policies

Not all telehealth platforms can prescribe controlled substances due to federal regulations. For instance, Teladoc Health does not prescribe medications like Adderall or Ambien. Always confirm your provider's policies before scheduling.

💰 Understand Costs

Costs for telehealth consultations vary. Some platforms may use subscription models, while others charge per visit. It’s important to check with your chosen provider for their specific pricing.

📅 Scheduling Flexibility

Processing times for telehealth prescriptions can differ by provider. Some may offer same-day consultations, while others could take longer to schedule an appointment.

📝 Complete Necessary Forms

For buprenorphine treatment via telemedicine, patients should complete any required intake forms before their consultation. This helps streamline the process and ensures a thorough evaluation.

🏆 Services Ranked by User Reviews (2026)

This section covers various online healthcare services relevant to telehealth and controlled substances. The rankings follow Trustpilot data from October 2026. While star ratings highlight customer satisfaction, reviews can vary widely.

🥇 1. Hims & Hers Health

Hims & Hers Health holds a Trustpilot score of 3.0. This service is known for providing online healthcare services, including prescription medications and personal care products. However, reviewers have noted customer service issues and concerns regarding product effectiveness.

🥈 2. LifeStance Health

LifeStance Health has a Trustpilot rating of 4.0. It specializes in mental health services, including therapy and psychiatry, with telehealth options available. Despite its positive ratings, some customers have reported inconsistent service quality and challenges with appointment availability.

🥉 3. Talkiatry

Talkiatry averages a Trustpilot score of 2.4. This platform offers online psychiatry services and medication management. However, reviewers mention limited insurance coverage and variable clinician quality, which can affect the overall experience.

4️⃣ Direct Meds

Direct Meds has a Trustpilot score of 4.6. This service is recognized for its telehealth options concerning GLP-1 medications, such as compounded semaglutide and tirzepatide. Users appreciate the quality verification, but it may have limited insurance acceptance and some potential medication side effects.

🆓 Free Government and Nonprofit Help

The U.S. Department of Labor provides assistance related to the Mental Health Parity and Addiction Equity Act. Patients can reach out to the Employee Benefits Security Administration for more information.

Additionally, the Substance Abuse and Mental Health Services Administration offers a national helpline for support and treatment referrals.

🔎 What to Compare When Choosing Services

  • 🩺 Service offerings: Look at the types of prescriptions available.
  • 💻 Telehealth capabilities: Check if video consultations are required.
  • 💵 Cost structure: Understand pricing models and insurance acceptance.
  • 🌟 User reviews: Evaluate Trustpilot scores and feedback.

❓ Frequently Asked Questions

❔ What are the requirements for telehealth prescriptions?

Patients must have a video consultation with a DEA-registered practitioner to qualify for telehealth prescriptions of controlled substances.

🕒 How long does it take to get a telehealth prescription?

Processing times vary by provider. Some may offer same-day consultations, while others may require several days for scheduling.

💰 Are telehealth consultations covered by insurance?

Coverage for telehealth consultations varies by insurance plan. Patients should check with their insurance provider to understand coverage for telehealth services.

📅 Can I start buprenorphine treatment anytime?

Yes, there are no specific deadlines for initiating buprenorphine treatment via telemedicine. Patients can seek treatment whenever needed.

🔍 What is the Mental Health Parity and Addiction Equity Act?

The MHPAEA is a law that requires mental health and substance use disorder benefits to be treated the same as medical and surgical benefits, ensuring equal coverage.

📞 Where can I find free help for substance use disorders?

The Substance Abuse and Mental Health Services Administration offers a national helpline for individuals seeking support and treatment referrals for substance use disorders.

⚖️ Recent Cases Related to Drug Law

There have been recent court rulings impacting drug law and telehealth regulations, which connect to the topics of controlled substances and prescription medications.

For more insights, feel free to browse more rulings on the news page.

End of October 2026 Update






 



What is Pergolide?



 

Pergolide-Permax


 



Also referred to as Permax, Pergolide is an ergoline-based dopamine receptor used in some countries for the treatment of Parkinson’s disease. 



Parkinson’s is associated with abnormally low levels of the neurotransmitter dopamine in the brain Pergolide (commercial name Permax) attempts to mimic—and yield similar effects--as dopamine in the body.



 



 



Although effective in numerous case studies, Pergolide was withdrawn from the United States consumer markets for human use. The ban came after several published studies revealed a link between Pergolide and increased rates of valvular dysfunction. Although banned for human use, Pergolide is applied for use in animals, particularly horses, to treat Cushing’s syndrome.



Pergolide (Permax) is provided via oral administration in tablets. With Pergolide acting as the base, the tablets utilize microcrystalline cellulose, magnesium stearate, lactose monohydrate, sodium starch glycolate and pregelatinized starch. 



 



 



As a dopamine receptor agonist, Pergolide (Permax) is 10 to 1000 times stronger than bromocriptine on a milligram per milligram basis. Pergolide (Permax) impedes the secretion of prolactin in human beings; Pergolide (Permax) causes a transient increase in serum concentrations of growth hormones and a steady decrease in serum concentrations of luteinizing hormones. To combat Parkinson’s disease, Pergolide (Permax) is thought to exert a therapeutic effect by stimulating post-synaptic dopamine receptors in the body’s nigrostriatal system. 



 



 



Is Pergolide Banned Throughout the World?



 



 



Pergolide (Permax) is not available in the United States; however, it is still commonly used in a handful of countries for the treatment of various conditions, including restless leg syndrome, hyperprolactinemia and Parkinson’s disease. Moreover, Pergolide (Permax) is also used for veterinary purposes—the drug is commonly used to treat pituitary par intermedia hyperplasia or—as stated above—Equine Cushing’s Syndrome in horses. 



 



 



Side Effects of Pergolide:



 



 



Pergolide, which has significantly decreased with regards to circulation and use, is commonly associated with a form of heart disease called cardiac fibrosis. In 2007, the Food and Drug Administration declared a voluntary withdrawal of Pergolide (Permax) by manufacturers because of the increased possibility of heart valve damage. As stated above, Pergolide (Permax) is not available in the United States. 



 



 



The dangerous side effects yielded by Pergolide (Permax) are thought to be caused by the drug’s action at the 5-HT serotonin receptor of cardiac myocytes; this effect causes proliferative valve disease in a similar manner to other serotonin agonists. Pergolide (Permax) can also cause Raynaud’s phenomenon and impair associative learning. 



 



 



Patients using Pergolide (Permax) commonly report falling asleep while engaged in daily activities, including driving a car. Although a number of patients reported somnolence while taking Pergolide (Permax), a large percentage reported a lack of warning signs such as drowsiness before falling asleep. 



 



 



In Clinical trials, roughly 10% of patients taking Pergolide (Permax) exhibited signs of symptomatic hypotension, especially during the initial phases of treatment. With gradual increase of Pergolide (Permax), patients grew tolerant of the hypotension. It is therefore necessary to be cognizant of the risk; treatment must begin with low doses and only increase if the patient can tolerate hypotension. Typically, dosage is increased over a period of 3 to 4 weeks. 



 



 



In controlled tests, Pergolide (Permax) caused hallucinations in roughly 15% of patients. The hallucinations were intense enough to cause a discontinuation in roughly 3% of those affected. 



I a placebo-controlled test, 2 of 187 patients treated with Pergolide (Permax) died. Of the 2,3000 patients treated with Pergolide (Permax) in premarketing tests (conducted in the late 1980’s), 143 patients died while under the drug or shortly after taking it. Because the patient population under evaluation was ill, elderly, and/or facing increased risks of death, it was affirmed that Pergolide (Permax) played a minor role in these fatalities. However, the possibility that Pergolide (Permax) shortens survival times cannot be excluded with absolute certainty. 



 



 



In addition to the physical ailments caused by Pergolide (Permax), the drug has reported to cause unique psychological alterations. In Britain, for example, select users of Pergolide (Permax) claim that the drug has caused them to develop severe gambling addictions. In June of 3010, similar reports surfaced in Australia; users of Pergolide (Permax) are suing the manufacturer over both gambling and sex addiction problems they claim resulted from the use of the drug. 



 



 



In March of 2007, manufacturers of Pergolide (Permax) agreed to withdraw the medication from the United States after a number of published studies revealed a link between the drug and heightened rates of valvular dysfunction. 



 



 



In addition to the aforementioned side effects, Pergolide (Permax) causes a significant decrease in appetite during the first week of use. Other side effects commonly associated with Pergolide (Permax) include: anemia, respiratory infections, hallucinations, dizziness, headache and low blood-pressure. 



 



 



Pergolide (Permax) Recall and Legal Information:



 



 



A gradual recall of Pergolide (Permax) was announced on March 30th of 2007. The recall was announced by officials within the United States Food and Drug Administration and came after a decade of progressively increased warnings by both the Food and Drug Administration and the drug’s parent company, Eli Lilly. 



 



 



If you or a loved one has suffered a serious injury or death as a result of Pergolide (Permax), you must immediately contact a law firm that specializes in mass torts, drug side effect lawsuits or personal injury laws. These types of law firms will handle Pergolide (Permax) associated legislation in all 50 states throughout the U.S. 



 



 



Those victims filing lawsuits against manufacturers of Pergolide (Permax) commonly seek compensation for the following side effects:



 



 



1.Primary Pulmonary Hypertension



 



 



2.Heart-Valve Damage (Mitral and Aortic Valve injuries)



 



 



3.Valvular heart diseases



 



 



4.Cardiac valvulopathy



 



 



5.Leaky heart valves



 



 



6.Pulmonary fibrosis (pleural, pericardial and/or retroperitoneal fibrosis)